EFM
E Fund Management Portfolio holdings
AUM
$2.1B
This Quarter Return
+12.44%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$1.31B
AUM Growth
+$1.31B
(+3.9%)
Cap. Flow
-$33.1M
Cap. Flow
% of AUM
-2.52%
Top 10 Holdings %
Top 10 Hldgs %
65.03%
Holding
329
New
20
Increased
146
Reduced
123
Closed
37
Top Buys
| 1 |
KLA
KLAC
|
$9.71M |
| 2 |
Pinduoduo
PDD
|
$8.56M |
| 3 |
iShares Gold Trust
IAU
|
$3.24M |
| 4 |
SPDR Gold MiniShares Trust
GLDM
|
$3.14M |
| 5 |
iShares MSCI Global Gold Miners ETF
RING
|
$3.08M |
Top Sells
| 1 |
Grab
GRAB
|
$40.9M |
| 2 |
NVIDIA
NVDA
|
$7.48M |
| 3 |
Microsoft
MSFT
|
$5.75M |
| 4 |
STAAR Surgical
STAA
|
$4.82M |
| 5 |
Sea Limited
SE
|
$3.38M |
Sector Composition
| 1 | Consumer Discretionary | 45.37% |
| 2 | Technology | 25.37% |
| 3 | Communication Services | 8.93% |
| 4 | Healthcare | 6.43% |
| 5 | Real Estate | 6.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
ADMA Biologics
ADMA
$4.06B
| $115K | 0.01% |
32,129
-6,484
| -17% | -$23.2K |
|
277
Arcutis Biotherapeutics
ARQT
$1.86B
| $114K | 0.01% |
21,535
-5,342
| -20% | -$28.3K |
|
278
Seres Therapeutics
MCRB
$169M
| $114K | 0.01% |
48,095
+6,514
| +16% | +$15.4K |
|
279
CareDx
CDNA
$679M
| $110K | 0.01% |
15,683
-2,754
| -15% | -$19.3K |
|
280
Kura Oncology
KURA
$724M
| $109K | 0.01% |
11,929
+1,301
| +12% | +$11.9K |
|
281
Avidity Biosciences
RNA
$6.03B
| $108K | 0.01% |
16,965
-12,499
| -42% | -$79.6K |
|
282
Viatris
VTRS
$12.3B
| $105K | 0.01% |
10,641
-1,375
| -11% | -$13.6K |
|
|
AGEN
283
Agenus
AGEN
$136M
| $98K | 0.01% |
86,343
+9,031
| +12% | +$10.3K |
|
284
Aldeyra Therapeutics
ALDX
$351M
| $93K | 0.01% |
13,939
+327
| +2% | +$2.18K |
|
285
Anavex Life Sciences
AVXL
$825M
| $91K | 0.01% |
13,908
-4,945
| -26% | -$32.4K |
|
286
MiMedx Group
MDXG
$1.04B
| $84K | 0.01% |
+11,535
| New | +$84K |
|
|
PNT
287
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $76K | 0.01% |
11,463
+939
| +9% | +$6.23K |
|
288
Sana Biotechnology
SANA
$721M
| $65K | ﹤0.01% |
16,688
-1,366
| -8% | -$5.32K |
|
|
EQRX
289
DELISTED
EQRx, Inc. Common Stock
EQRX
| $60K | ﹤0.01% |
26,843
-6,479
| -19% | -$14.5K |
|
290
Scilex Holding
SCLX
$128M
| $44K | ﹤0.01% |
31,431
| – | – |
|
291
Lyell Immunopharma
LYEL
$220M
| $32K | ﹤0.01% |
21,829
+4,338
| +25% | +$6.36K |
|
292
Mersana Therapeutics
MRSN
$35.4M
| – | – |
-18,105
| Closed | -$60K |
|
|
ALLK
293
DELISTED
Allakos
ALLK
| – | – |
-18,996
| Closed | -$83K |
|
294
Arcturus Therapeutics
ARCT
$469M
| – | – |
-8,523
| Closed | -$244K |
|
295
Boeing
BA
$175B
| – | – |
-945
| Closed | -$200K |
|
296
BioXcel Therapeutics
BTAI
$51.1M
| – | – |
-10,628
| Closed | -$71K |
|
297
Carnival Corp
CCL
$42.2B
| – | – |
-71,320
| Closed | -$1.34M |
|
298
Cogent Biosciences
COGT
$1.8B
| – | – |
-11,088
| Closed | -$131K |
|
299
Emergent Biosolutions
EBS
$427M
| – | – |
-31,274
| Closed | -$230K |
|
300
Edwards Lifesciences
EW
$47.2B
| – | – |
-2,126
| Closed | -$201K |
|